Business Context and Reporting Period
Company: Autolus Therapeutics Plc
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2024
Reporting Period: Event-based disclosure regarding clinical data presentation.
The filing serves as a Regulation FD disclosure to announce the presentation of clinical data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The Company is incorporated in England and Wales and its American Depositary Shares trade on The Nasdaq Global Select Market under the symbol "AUTL".
Key Financial Metrics
This Form 8-K is a current report focused on clinical developments and does not contain financial statements, revenue figures, profit data, cash flow information, margin analysis, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes
There are no material changes to financial position or operations reported in this document. The material event disclosed is the release of longer-term follow-up and additional data analysis from the pivotal Phase Ib/II FELIX study of obecabtagene autoleucel (obe-cel) for relapsed/refractory adult B-cell Acute Lymphoblastic Leukemia (ALL).
Guidance, Outlook, and Management Commentary
- Clinical Update: Management highlighted data from the FELIX study presented at ASCO 2024.
- Investor Communication: A conference call and webcast were held on June 1, 2024, to discuss the presented data. The presentation slides are furnished as Exhibit 99.2.
- Legal Disclaimer: The press release and presentation materials are not deemed "filed" under the Exchange Act and are not incorporated by reference into other filings unless expressly stated.
- Outlook: No specific financial guidance or future revenue projections are included in this filing.
Key Facts for Investor Verification
- Verify the specific clinical outcomes and statistical significance of the longer-term follow-up data from the FELIX study in the press release (Exhibit 99.1).
- Review the corporate presentation (Exhibit 99.2) for management's interpretation of the data and potential impact on regulatory pathways.
- Confirm the Company's cash runway and burn rate in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor subsequent filings for any updates on regulatory submissions or partnership discussions triggered by the ASCO data.